168 related articles for article (PubMed ID: 20705614)
21. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
22. Gene expression changes in melanoma metastases in response to high-dose chemotherapy during isolated limb perfusion.
Wouters J; Stas M; Govaere O; Van den Eynde K; Vankelecom H; van den Oord JJ
Pigment Cell Melanoma Res; 2012 Jul; 25(4):454-65. PubMed ID: 22486811
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
Winnepenninckx V; van den Oord JJ
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
[TBL] [Abstract][Full Text] [Related]
24. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
25. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
26. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
[TBL] [Abstract][Full Text] [Related]
27. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
28. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
29. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R;
Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761
[TBL] [Abstract][Full Text] [Related]
30. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer.
Winsey SL; Haldar NA; Marsh HP; Bunce M; Marshall SE; Harris AL; Wojnarowska F; Welsh KI
Cancer Res; 2000 Oct; 60(20):5612-6. PubMed ID: 11059748
[TBL] [Abstract][Full Text] [Related]
31. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
32. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
[TBL] [Abstract][Full Text] [Related]
33. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Mori T; O'Day SJ; Umetani N; Martinez SR; Kitago M; Koyanagi K; Kuo C; Takeshima TL; Milford R; Wang HJ; Vu VD; Nguyen SL; Hoon DS
J Clin Oncol; 2005 Dec; 23(36):9351-8. PubMed ID: 16361635
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in genes involved in DNA repair, cell growth, oxidative stress and inflammatory response, and melanoma risk.
Gu F; Qureshi AA; Kraft P; Guo Q; Hunter DJ; Han J
Br J Dermatol; 2009 Jul; 161(1):209-12. PubMed ID: 19438866
[No Abstract] [Full Text] [Related]
37. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Giovannetti E; Pacetti P; Reni M; Leon LG; Mambrini A; Vasile E; Ghidini M; Funel N; Lucchesi M; Cereda S; Peters GJ; Cantore M
Pharmacogenomics; 2011 Dec; 12(12):1641-52. PubMed ID: 22026922
[TBL] [Abstract][Full Text] [Related]
38. Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes.
Kucherlapati M
BMC Cancer; 2018 Aug; 18(1):818. PubMed ID: 30107825
[TBL] [Abstract][Full Text] [Related]
39. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
Bedikian AY; Garbe C; Conry R; Lebbe C; Grob JJ;
Melanoma Res; 2014 Jun; 24(3):237-43. PubMed ID: 24667300
[TBL] [Abstract][Full Text] [Related]
40. Biallelic somatic inactivation of the mismatch repair gene MLH1 in a primary skin melanoma.
Castiglia D; Pagani E; Alvino E; Vernole P; Marra G; Cannavò E; Jiricny J; Zambruno G; D'Atri S
Genes Chromosomes Cancer; 2003 Jun; 37(2):165-75. PubMed ID: 12696065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
